5/5/2014 8:54:54 AM
FLEMINGTON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that abstracts outlining two, separate ongoing Phase I clinical trials evaluating its investigational lead compound onapristone have been accepted for poster presentation at the upcoming 50th American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2014 in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
comments powered by